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Abstract
Background: The effect of long- term surveillance for asymptomatic patients after 
curative resection of gastric cancer is being debated. We compared the prognosis of 
Korean patients with recurrent gastric cancer according to the presence or absence of 
cancer- related symptoms at the time of recurrence detection.
Methods: We retrospectively reviewed the medical records of 305 Korean patients 
who experienced recurrence after curative resection of primary gastric cancer be-
tween March 2002 and February 2017 at Yonsei Cancer Center, Yonsei University 
College of Medicine, Seoul, Republic of Korea.
Results: The median follow- up duration was 169.8 months (1– 267.2), and the me-
dian age at first recurrence was 58.1  years (23.4– 81.9). Among 305 patients with 
recurrence, 97 of 231 (42.0%) patients with early recurrence (≤5 years after cura-
tive surgical resection) and 47 of 74 (63.5%) patients with late recurrence (>5 years 
after curative surgical resection) had cancer- related symptoms at recurrence 
(p  =  0.001). For survival after recurrence, detection of asymptomatic recurrence 
was an independent favorable factor (hazard ratio, 0.527; 95% confidence interval, 
0.409– 0.681; p < 0.001) accompanied with the possibility of subsequent treatment, 
targeted- , or immunotherapy for recurrent disease, and locoregional recurrence only. 
In the late- recurrence group, the patients with asymptomatic detection of recurrence 
showed favorable post- recurrence survival (median, 33.3 months vs. 14.7 months; 
p = 0.002), overall survival (median, 136.3 months vs. 106.1 months; p = 0.010), and 
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1 |  INTRODUCTION
Despite the incidence and mortality rates of gastric cancer de-
creasing in recent decades, it is still one of the most common 
cancers, particularly in East Asia.1 Meanwhile, with cancer 
screening and treatment advancements, the number of gastric 
cancer survivors also continues to increase. In Korea, gastric 
cancer patients have a 76.5% 5- year survival rate, and long- 
term (beyond 5 years from diagnosis) gastric cancer survivors 
exceeded 172,000 in 2017.2 Among the long- term survivors, 
some patients experience cancer recurrence even 5– 10 years 
after curative resection. However, although global clinical 
guidelines recommend active surveillance programs, includ-
ing physical examination, endoscopy, blood tests, computed 
tomography, or ultrasonography within 5 years of the curative 
treatment of disease, most do not provide detailed surveillance 
recommendations after 5 years for long- term survivors.3– 6 As 
late recurrence is uncommon in most cancer types, and there 
is insufficient evidence for active surveillance in the long- term 
survivorship, surveillance and screening methods usually de-
pend on physicians’ discretion in clinical practice.
In recent years, many researchers have demonstrated 
the lack of survival benefit of active surveillance for stom-
ach cancer recurrence after curative resection.7– 10 Early 
detection of recurrence in asymptomatic patients facili-
tated prompt cancer treatment, resulting in a better clinical 
status; therefore, “asymptomatic patients” lived slightly 
longer than patients with late symptomatic detection. In 
contrast, symptomatic patients usually had a higher tumor 
burden than asymptomatic patients, as tumors grew and 
invaded organs during the symptom- free period. Despite 
this, because the post- recurrent survival benefit could not 
surpass the symptom- free period of symptomatic patients, 
previous studies have not shown the overall survival (OS) 
benefit of asymptomatic detection of recurrence. However, 
several improvements have been made in the area of post- 
recurrent treatment: chemotherapy, targeted therapy, im-
munotherapy, as well as endoscopic and surgical resection 
for gastric cancer. Due to the rapid increase in the number 
of gastric cancer survivors, there is a need to reconsider 
whether early detection of recurrence by active surveil-
lance and subsequent cancer treatment might improve the 
survival of patients who underwent curative resection of 
primary gastric cancer.
In this study, we analyzed whether the survival of pa-
tients with recurrent gastric cancer was different according 
to the presence or absence of cancer- related symptoms at the 
time of detection of recurrence. Especially, the correlation 
between symptomatic recurrence and survival outcomes was 
explored in both early (≤5  years after curative surgical re-
section) and late (>5 years after curative surgical resection) 
recurrence groups.
2 |  PATIENTS AND METHODS
2.1 | Study population
This study included patients who had undergone curative 
resection of gastric cancer with recurrence between March 
2002 and February 2017 at Yonsei Cancer Center, Yonsei 
University College of Medicine, Seoul, Republic of Korea. 
The criteria for eligibility were as follows: (i) histologically 
proven gastric or gastroesophageal adenocarcinoma, (ii) age 
of ≥18 years at the time of the first diagnosis of gastric can-
cer, (iii) operable disease at initial diagnosis and a history of 
curative surgical resection, and (iv) presence of recurrence 
confirmed by the pathological diagnosis of tumoral tissue in 
the recurrent site or definite image study.
Based on a prospectively compiled database, we enrolled 
305 Korean patients who met the eligibility criteria and ret-
rospectively reviewed their medical records. Information on 
sex, patient's age at diagnosis, histological classification, 
microsatellite instability status, human epidermal growth 
factor receptor 2 (HER2) status, TNM staging according to 
the American Joint Committee on Cancer staging manual 8th 
edition,11 time of recurrence, sites of recurrence, treatment 
for recurrence, survival duration, and cause of death were ob-
tained. The protocol was approved by the institutional review 
board (IRB) of the Severance Hospital, Yonsei University 
cancer- specific survival (median, 177.5 months vs. 106.1 months; p = 0.005) than the 
patients with symptomatic detection.
Conclusion: The detection of gastric cancer recurrence in patients without cancer- 
related symptoms may be related to improved survival, suggesting the potential ben-
efit of long- term surveillance.
K E Y W O R D S
early detection of cancer, recurrence, stomach neoplasms, survivorship
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Health System, Seoul, Republic of Korea (4- 2019- 0791). 
Informed consent was waived by the decision of IRB.
2.2 | Definition of terms
Early recurrence was defined as recurrence detected within 
5  years from the first curative resection of primary gastric 
cancer, whereas late recurrence was defined as recurrence 
detected beyond 5 years from the first curative resection.
Cancer- related symptoms included aggravation of symp-
toms relevant to the recurrent site (e.g., cough or dyspnea 
for lung or pleural metastasis; nausea, vomiting, or severe 
abdominal distension for intestinal or peritoneal metastasis) 
as well as general symptoms of suspicious recurrence (e.g., 
abnormal weight loss and persistent, deteriorated, and poorly 
controlled pain). In this study, symptomatic recurrence was 
defined as the presence of cancer- related symptoms reported 
by the patients when recurrence was detected.
Relapse- free survival (RFS) was defined as the date of cu-
rative tumor resection to the first recurrence date. OS was de-
fined as the date of first curative resection to the date of any 
cause of death. Cancer- specific survival (CSS) was defined 
as the date of first curative resection to the date of death by 
gastric cancer progression. For the CSS analysis, death from 
other causes (e.g., acute infection, other primary malignancy, 
or suicide) was not considered an event. Post- recurrence sur-
vival (PRS) was defined from the recurrence detection date 
to the date of any cause of death.
2.3 | Adjuvant treatment and routine 
surveillance program
In this study, patients with high- risk stage II or stage III dis-
ease were recommended to be treated with adjuvant chem-
otherapy. Adjuvant chemotherapeutic regimens included 
5- fluorouracil (5- FU) or TS- 1 monotherapy, 5- FU or TS- 1 
plus cisplatin, capecitabine plus oxaliplatin, TS- 1 plus doc-
etaxel, and 5- FU plus doxorubicin combination therapy. After 
completion of curative surgical resection and/or adjuvant 
treatment, patients visited the clinic. They underwent rou-
tine follow- up evaluation following the institutional proto-
col, which consisted of history taking, physical examination, 
hematological and chemistry tests, tumor marker detection, 
anemia profiling, chest radiography, abdominopelvic com-
puted tomography, or sonography, every 3  months for the 
first 2 years and every 6 months thereafter for 5 years. Upper 
endoscopic evaluation (esophagogastroduodenoscopy) was 
performed annually. Beyond 5  years after curative resec-
tion, the gastric cancer survivors were recommended to visit 
the clinic annually for history taking, physical examination, 
blood tests, and endoscopic assessment. Imaging studies and 
further evaluation were considered based on cancer- related 
symptoms, risk factors, and comorbidities of the patients.
2.4 | Statistical analysis
This study's primary objective was to compare the patient 
OS according to the presence or absence of cancer- related 
symptoms at the time of diagnosis of recurrence. The sec-
ondary objective was to compare the CSS and PRS in terms 
of cancer- related symptoms at recurrence and the time of 
recurrence between the early- and late- recurrence groups. 
Clinicopathological characteristics and treatment- related 
factors were analyzed using Chi- square, Fisher's exact, 
and Mann– Whitney U tests between the early- and late- 
recurrence groups. The Kaplan– Meier method and Cox's 
proportional hazard model were used for survival analysis, 
and survival curves were compared using the log- rank test. 
For survival analyses, stage of primary gastric carcinoma, 
type and time of recurrence, and subsequent treatment for 
the recurrent disease were also analyzed as the possible con-
founding variables. A p  ˂  0.05 was considered statistically 
significant. All statistical analyses were performed using 
SPSS 25 for Windows (IBM Corp.).
3 |  RESULTS
3.1 | Differences in clinicopathological 
factors between the patients with early and late 
recurrence
Among 305 patients with recurrent gastric cancer, 231 pa-
tients (75.7%) were classified into the early- recurrence 
group (within 5 years), and 74 patients (24.3%) into the late- 
recurrence group (beyond 5 years). The median RFS duration 
of all patients, the early- recurrence group, and the late- 
recurrence group were 32.1  months (95% CI, 27.1– 37.1), 
22.5 months (95% CI, 20.2– 24.8), and 87.9 months (95% CI, 
80.0– 95.4), respectively. Clinicopathological characteristics 
are shown in Table 1.
The initial TNM stage of primary gastric cancer was 
slightly higher in the early- recurrence group (stage I, II, and 
III: 11.7%, 14.3%, and 73.1%, respectively) than in the late- 
recurrence group (p < 0.001). Although the proportion of the 
patients who were treated with adjuvant chemotherapy was 
higher in the early- recurrence group (70.6%) than in the late- 
recurrence group (47.3%, p = 0.001), the proportions only 
among the patients with stage II or III disease were not differ-
ent between the two groups (81.1% in early- recurrence group 
vs. 75.9% in late- recurrence group, p = 0.515). Locoregional 
recurrence (limited to the stomach and regional lymph nodes) 
was more frequently found in the late- recurrence group 
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T A B L E  1  Clinicopathological characteristics of the patients in early- and late- recurrence group
Variables
Early- recurrence (N = 231) Late- recurrence (N = 74)
p- valueN % N %
Sex
Male 155 67.1% 52 70.3% 0.611
Female 76 32.9% 22 29.7%
Characteristics of primary gastric carcinoma
Age at diagnosis [years] 
(median, range)
55 (23.4– 81.9) 51.2 (28.5– 75.4) 0.269
TNM stage according to AJCC8
I 27 11.7% 23 31.1% <0.001a 
II 33 14.3% 10 13.5%
III 169 73.1% 30 40.5%




6 2.6% 8 10.8% 0.085
Adenocarcinoma, moderately 
differentiated
60 26.0% 19 25.7%
Adenocarcinoma, poorly 
differentiated
108 46.8% 29 39.2%
Signet ring cell carcinoma 41 17.7% 14 18.9%
Others 16 6.9% 4 5.4%
Lauren classification (N =265)
Intestinal 85 38.5% 16 36.4% 0.840a 
Diffuse 126 57.0% 27 61.4%
Mixed 10 4.5% 1 2.2%
MSI status (N = 164)
MSI- high 2 1.3% 1 7.7% 0.262a 
MSI- low 5 3.3% 0 0.0%
MSS 144 95.4% 12 92.3%
HER2 status (N = 258)
Positive 15 7.1% 2 4.2% 0.747a 
Negative 195 92.9% 46 95.8%
Adjuvant chemotherapy
Yes 163 70.6% 35 47.3% 0.001
No 68 29.4% 39 52.7%
Characteristics of recurrence
Age at recurrence [years] 
(median, range)
57.6 (26– 82.5) 62.7 (33.7– 83.3) 0.117
Site of recurrence
Locoregional recurrence 19 8.2% 14 18.9% 0.010
Distant recurrence (multiple selection)
Distant lymph nodes 47 20.3% 9 12.2% 0.114
Peritoneum 120 51.9% 28 37.8% 0.035
Krukenberg tumor 20 8.7% 4 5.4% 0.366
Liver 40 17.3% 11 14.9% 0.623
(Continues)
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(18.9%) than in the early- recurrence group (8.2%, p = 0.010). 
Peritoneal recurrence tended to be more frequent in the early- 
recurrence group (51.9%) than in the late- recurrence group 
(37.8%, p = 0.035). Among minor types of recurrence, the 
late- recurrence group showed more frequent pancreatic me-
tastasis (5.4% vs. 0%; p = 0.003) and brain metastasis (5.4% 
vs. 0%; p = 0.003) than the early- recurrence group.
Among the late- recurrence group, 17 patients experienced 
recurrence more than 10 years after the curative surgical re-
section of primary gastric cancer. The clinicopathological 
features are listed in Table  S1. Most of the characteristics 
of the extremely late recurrence group (recurrence after 
>10 years) were not significantly different from those of the 
patients who experienced recurrence between 5 and 10 years. 
Anemia at detection of recurrence was more frequent in pa-
tients with recurrence after >10 years (82.4%) than in those 
with recurrence between 5 and 10 years (47.4%; p = 0.011).
Among 305 patients, 97 of 231 (42.0%) patients with 
early recurrence and 47 of 74 (63.5%) patients with late re-
currence had cancer- related symptoms at detection of recur-
rence (p < 0.001).
3.2 | Survival outcomes according 
to the presence and absence of cancer- 
related symptoms
As of 31 December 2019, 206 patients in the early- recurrence 
group (89.2%) and 58 patients in the late- recurrence 
group (78.4%) died. The median follow- up duration was 
169.8 months (range, 6.0– 267.2). Patients without symptoms 
at detection of recurrence lived longer than patients with 
symptoms at detection of recurrence in both subgroups of 
early recurrence (median PRS, 20.6 months [95% CI, 16.1– 
25.1] in asymptomatic vs. 10.8 months [95% CI, 8.3– 13.3] in 
symptomatic patients; p < 0.001) and late recurrence (median 
PRS, 33.3 months [95% CI, 20.1– 46.5] in asymptomatic vs. 
14.7 months [95% CI, 11.7– 17.7] in symptomatic patients; 
p = 0.002) (Figure 1A).
The OS was also longer in asymptomatic patients in the 
early- recurrence group (median OS, 48.2 [95% CI, 36.4– 
57.0] in asymptomatic vs. 36.3 months [95% CI, 28.5– 44.1] 
in symptomatic patients; p < 0.001) and in the late- recurrence 
group (median OS, 136.3 [95% CI, 55.7– 216.9] in asymp-
tomatic vs. 106.1 months [95% CI, 93.9– 118.3] in symptom-
atic patients; p = 0.010) (Figure 1B). In addition, the CSS 
was superior among the asymptomatic patients in the early- 
recurrence group (median CSS, 51.0 months in asymptomatic 
patients vs. 38.6 months in symptomatic patients; p < 0.001) 
and in the late- recurrence group (median CSS, 177.5 months 
in asymptomatic patients vs. 106.1 months in symptomatic 
patients; p = 0.005) (Figure 1C).
3.3 | Prognostic 
value of the detection of asymptomatic 
recurrence considering subsequent treatment
Among a total of 305 patients, 144 (47.2%) patients had 
cancer- related symptoms at recurrence (symptomatic detec-
tion group), and 161 (52.8%) patients did not have cancer- 
related symptoms at recurrence (asymptomatic detection 
group). Differences in the clinical factors and treatment ac-
cording to the presence of symptoms are listed in Table 2. 
There was a larger number of female patients (38.9% vs. 
26.1%; p  =  0.017), more peritoneal recurrence (61.1% vs. 
Variables
Early- recurrence (N = 231) Late- recurrence (N = 74)
p- valueN % N %
Lung 13 5.6% 10 13.5% 0.025
Bone 10 4.3% 11 14.9% 0.002
Pancreas 0 0% 4 5.4% 0.003a 
Brain 0 0% 4 5.4% 0.003a 
Others 2 0.9% 7 9.5% 0.001a 
Presence of anemiab 126 54.5% 41 55.4% 0.897
Symptom at detection of recurrence
Symptomatic 97 42.0% 47 63.5% 0.001
Asymptomatic 134 58.0% 27 36.5%
Abbreviations: AJCC, American Joint Committee on Cancer; AMD, adenocarcinoma, moderately differentiated; APD, adenocarcinoma, poorly differentiated; AWD, 
adenocarcinoma, well differentiated; HER2, human epidermal growth factor receptor 2; MSI, microsatellite instability; MSS, microsatellite stable; SRC, signet ring 
cell carcinoma.
aThese values were analyzed by Fisher's exact test.
bAnemia was defined as the hemoglobin level below 13 g/dl for males, below 12 g/dl for females.
T A B L E  1  (Continued)
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F I G U R E  1  Survival outcomes in the 
early- and late- recurrence groups according 
to the presence or absence of symptoms 
at the time of detection of gastric cancer 
recurrence. (A) The early- recurrence group 
and late- recurrence group were analyzed for 
post- recurrence survival. (B) Both groups 
were analyzed for overall survival. (C) Both 
groups were analyzed for cancer- specific 
survival. CSS, cancer- specific survival; N, 
number; OS, overall survival; PRS, post- 
recurrence survival
overall survival time from the first curative surgical resection (months)
Time from recurrence to any cause of death (months)




Group (N), Median PRS (95% CI)
Group (N), Median OS (95% CI)
Group (N), Median CSS (95% CI)
Early symptomatic recurrence (N=97), 10.8 (8.3-13.3)
Early asymptomatic recurrence (N=134), 20.6 (16.1-25.1)
Late symptomatic recurrence (N=47), 14.7 (11.7-17.7)
Late asymptomatic recurrence (N=27), 33.3 (20.1-46.5)
Early symptomatic recurrence (N=97), 36.3 (28.5-44.1)
Early asymptomatic recurrence (N=134), 48.2 (36.4-57.0)
Late symptomatic recurrence (N=47), 106.1 (93.9-118.3)
Late asymptomatic recurrence (N=27), 136.3 (55.7-216.9)
Early symptomatic recurrence (N=97), 38.6 (28.2-49.1)
Early asymptomatic recurrence (N=134), 51.0 (42.0-60.0)
Late symptomatic recurrence (N=47), 106.1 (93.9-118.3)












 **p-value = 0.005
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Variables
Presence of symptom 
(N = 144)
Absence of symptom 
(N = 161)
p- valueN % N %
Sex
Male 88 61.1% 119 73.9% 0.017
Female 56 38.9% 42 26.1%
Age at recurrence [years] 
(median, range)
59.1 (26– 83.3) 57.8 (33.5– 82.5) 0.931
Site of recurrence
Locoregional recurrence 8 5.6% 25 15.5% 0.005
Distant recurrence (multiple selection)
Distant lymph nodes 27 18.8% 29 18.0% 0.868
Peritoneum 88 61.1% 60 37.3% <0.001
Krukenberg tumor 12 8.3% 12 7.5% 0.776
Liver 19 13.2% 32 19.9% 0.119
Lung 13 9.0% 10 6.2% 0.352
Bone 17 11.8% 4 2.5% 0.001
Others 7 4.9% 2 1.2% 0.090a 
Treatment for recurrent disease
Operation only 0 0% 11 6.8% 0.002a 
Chemotherapy only 94 65.3% 97 60.3%
Radiotherapy only 4 2.8% 2 1.2%
Multimodality 33 22.9% 45 28.0%
CTx + OP (% of 
multimodality)
17 (51.5%) 31 (68.9%)
RTx + OP (% of 
multimodality)
3 (9.1%) 0 (0%)
Chemoradiation (% of 
multimodality)
12 (36.4%) 13 (28.9%)
Chemoradiation + OP (% 
of multimodality)
1 (3.0%) 1 (2.2%)
No (impossible or refuse) 13 9.0% 6 3.7%
Surgical resection of recurrent tumor
Operation with the aim of 
curative resection
6 4.2% 33 20.5% <0.001
Palliative surgical resection 15 10.4% 10 6.2%
Not done (impossible) 123 85.4% 118 73.3%
Chemotherapy for recurrent cancer
Done 124 86.1% 142 88.2% 0.586
Not done 20 13.9% 19 11.8%
Line of chemotherapy 2 (1– 5) 2 (1– 8) 0.113
Use of targeted therapy or immunotherapyb 
Done 17 11.8% 25 15.5% 0.346
Not done 127 88.2% 136 84.5%
Abbreviations: CTx, chemotherapy; OP, operation; RTx, radiotherapy.
aThis value was analyzed by Fisher's exact test.
bThese therapeutic drugs include trastuzumab, lapatinib, trastuzumab deruxtecan, ramucirumab, bevacizumab, 
onartuzumab, atezolizumab, pembrolizumab, nivolumab, afatinib, ipatasertib, olaparib, and other drugs 
currently under investigation.
T A B L E  2  Differences in clinical factors 
and treatment for recurrence according 
to the presence or absence of cancer- 
related symptoms at the time of recurrence 
detection
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37.3%; p < 0.001), more bone recurrence (11.8% vs. 2.5%; 
p = 0.001), and less locoregional recurrence (5.6% vs. 15.5%; 
p = 0.005) in the symptomatic detection group.
In terms of treatment, 286 (93.8%) patients underwent 
treatment for recurrent gastric cancer. The asymptomatic de-
tection group was more likely to be treated with curative or 
palliative surgical resection of the recurrent tumor (26.7% vs. 
14.6% in symptomatic detection; p = 0.009). Local control, 
which was defined as treatment including surgical resection 
and/or radiotherapy of the recurrent tumor, was provided to 
58 (36.0%) patients in the asymptomatic detection group 
and 37 (25.7%) patients in the symptomatic detection group 
(p = 0.042). Both groups received similar lines of chemother-
apy (median, two cycles: p = 0.113). Forty- two patients were 
also treated with targeted therapeutic or immunotherapeutic 
drugs, including drugs currently under investigation.
T A B L E  3  Clinical factors and treatment for recurrence with significance in terms of survival outcomes (using Cox hazard multiple regression 
model) (N = 305)
Variables N
Post- recurrence survival Cancer- specific survival Overall survival
HR 95% CI p- value HR 95% CI p- value HR 95% CI p- value
Characteristics of primary gastric carcinoma
Stage of primary gastric cancer (AJCC 8th edition) (N = 292)
I or II 93 1 1





33 1 1 1
Distant or multiple 
recurrence











74 0.200 0.136– 0.294 <0.001 0.201 0.138– 0.294 <0.001
Presence of cancer- related symptom at the time of diagnosis of recurrence
Presence 
(symptomatic)
144 1 1 1
Absence 
(asymptomatic)
161 0.527 0.409– 0.681 <0.001 0.675 0.513– 0.886 0.005 0.689 0.528– 0.899 0.006
Subsequent treatment for recurrent disease




19 1 1 1
Chemotherapy only 
(palliative)
191 0.271 0.164– 0.449 <0.001 0.641 0.394– 1.042 0.073 0.676 0.417– 1.097 0.113
Local control for 
recurrent tumora 
95 0.154 0.090– 0.265 <0.001 0.303 0.176– 0.519 <0.001 0.334 0.196– 0.570 <0.001
Targeted- or immunotherapy for recurrent gastric cancer
Not done 263 1 1 1
Done 42 0.498 0.341– 0.727 <0.001 0.626 0.425– 0.922 0.018 0.617 0.422– 0.903 0.013
Abbreviation: HR, hazard ratio.
aLocal control was defined as the treatment including surgical resection and/or radiotherapy of the recurrent tumor.
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After adjustment of several confounding variables, the 
detection of asymptomatic recurrence was found to be a 
favorable prognostic factor for PRS (HR, 0.527; 95% CI, 
0.409– 0.681; p < 0.001). The detection of recurrence in pa-
tients without cancer- related symptoms was also related to 
improved CSS (HR, 0.675; 95% CI, 0.513– 0.886; p = 0.005) 
and OS (HR, 0.689; 95% CI, 0.528– 0.899; p  =  0.006; 
Table  3). In terms of the treatment method for recurrent 
disease, local control (HR, 0.154; 95% CI, 0.090– 0.265; 
p < 0.001) and targeted- or immunotherapy (HR, 0.498; 95% 
CI, 0.341– 0.727; p < 0.001) were related to favorable PRS, 
conferring superior CCS and OS (Table 3). The median num-
ber of PRS patients who underwent local control treatment 
(N = 95), underwent palliative chemotherapy only (N = 191), 
and without treatment for recurrent disease (N = 19) were 
29.1  months (95% CI, 20.9– 37.3), 14.9  months (95% CI, 
12.6– 17.2), and 5.6 months (95% CI, 4.2– 7.0), respectively 
(p < 0.001; Figure 2).
In addition, we observed a few long- term survivors after 
treatment for recurrent disease. Twelve of 161 patients with 
asymptomatic recurrence (7.5%) and one of 144 patients 
with symptomatic recurrence (0.7%) are still alive without 
any clinical evidence of residual tumors (p = 0.004) for a 
median of 100.1 months (range, 36.5– 166.9) since the first 
recurrence of gastric cancer. Among the 13 long- term survi-
vors, seven patients underwent completion of total gastrec-
tomy for the lesions limited in the stomach, three patients 
underwent metastasectomy (liver and ovary) followed by 
chemotherapy, two patients were treated with concurrent 
chemoradiation therapy, and one patient experienced the 
disappearance of a metastatic nodule during continuous 
chemotherapy.
4 |  DISCUSSION
In the present study, we demonstrated that the detection of 
gastric cancer recurrence after curative surgical resection in 
patients without cancer- related symptoms might be related to 
favorable OS, CSS, and survival after recurrence in both the 
early- and late- recurrence groups.
Early detection of primary cancer usually increases the 
efficacy of treatment. A possible explanation is that local-
ized disease can be treated with curative surgical or endo-
scopic resection. Furthermore, even in unresectable disease, 
the performance status and major organ function are suitable 
for active systemic treatment. Similarly, active surveillance 
is recommended for the early detection of cancer recurrence 
after curative surgical resection. However, the possibility of 
surgical resection of metastatic tumors and the efficacy of 
subsequent chemotherapy were limited in patients with gas-
tric cancer until recently. Moreover, most recurrent cases 
happen within 5 years after curative surgical resection; both 
physicians and patients pay less attention to gastric cancer 
recurrence beyond 5 years after curative surgical resection. 
Therefore, active surveillance for asymptomatic long- term 
gastric cancer survivors is uncommon in clinical practice. In 
this study, the detection of recurrence without cancer- related 
symptoms was more common in the early- recurrence group 
(58.0%) than in the late- recurrence group (36.5%, p = 0.001), 
which is probably due to the greater number of active sur-
veillance programs recommended,3– 6,10 and applied within 
5 years after curative surgical resection. The changing pro-
portion of asymptomatic detection over time possibly af-
fected the survival analysis of the patients according to the 
symptom. Our data showed that the median OS duration was 
F I G U R E  2  Post- recurrence survival 
according to the type of treatment for 
recurrent disease. PRS, post- recurrence 
survival
Local control (N=95), 29.1 months  (20.9 - 37.3)
Palliative chemotherapy only (N=191), 14.9 months (12.6 - 17.2)
No treatment (N=19), 5.6 months (4.2 - 7.0)
Group (N), Median PRS (95% CI)
p-value < 0.001
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59.7 months (95% CI, 47.8– 71.6) in all the patients with symp-
tomatic recurrence and 57.7 months (95% CI, 50.1– 65.3) in 
all the patients without symptomatic recurrence (p = 0.111). 
However, the results of the time- dependent Cox model (HR, 
0.640; 95% CI, 0.495– 0.827; p = 0.001) subgroup analysis in 
the early- and late- recurrence group (Figure 1) and multiple 
regression analysis (Table 3) represented the significance of 
detection of asymptomatic recurrence. Therefore, although 
the OS outcome of late asymptomatic recurrence did not ex-
ceed those of early symptomatic recurrence (Figure 1B,C), 
we suggest that the effort for detection of late recurrence at 
the time of asymptomatic status could be considered in the 
group of long- term gastric cancer survivors beyond 5 years 
from curative resection.
Several recent studies showed that the detection of as-
ymptomatic recurrence was related to improved survival out-
comes,11,12 in contrast to other reports.7– 9 Considering that 
even the studies not showing the efficacy of detecting asymp-
tomatic recurrence generally agreed that there is a correlation 
between asymptomatic recurrence and prolonged survival 
after recurrence, the treatments for recurrent disease possibly 
affected the different survival outcomes. Therefore, in this 
study, we analyzed survival outcomes not only according to 
the presence of symptoms but also the subsequent treatment 
for recurrent disease, the stage of primary cancer, and char-
acteristics of recurrence. As a result, the possibility of sur-
gical resection of recurrent tumors was related to improved 
OS (HR, 0.454; 95% CI, 0.310– 0.664, p = 0.002), CSS (HR, 
0.432; 95% CI, 0.291– 0.642, p < 0.001), and prolonged PRS 
(HR, 0.460; 95% CI, 0.316– 0.670, p  <  0.001). Even local 
control of the recurrent tumor with curative or palliative 
treatment was related to prolonged OS (HR, 0.334; 95% CI, 
0.196– 0.570, p < 0.001), CSS (HR, 0.303; 95% CI, 0.176– 
0.519, p  <  0.001), and PRS (HR, 0.154; 95% CI, 0.090– 
0.265, p < 0.001; Table 3). In addition, recent advances in 
novel treatment options, including the targeted therapies for 
HER2,13 vascular endothelial growth factor 2 (VEGFR2),14,15 
and immunotherapy16 for recurrent disease, possibly im-
proved the survival outcomes. In addition, because the sec-
ond and subsequent chemotherapy lines were also found to be 
effective and tolerable to patients,17,18 active treatment for the 
recurrent disease was applied more frequently than before. In 
fact, in this study, the patients who were treated with targeted 
therapy, including HER2 monoclonal antibody, VEGFR2 
monoclonal antibody, and immunotherapy, showed superior 
survival outcomes compared to those who were not treated 
with such methods (HR for OS, 0.617; 95% CI, 0.422– 0.903; 
p  =  0.013; Table  3). These active treatments for recurrent 
disease probably improved PRS of the asymptomatic patients 
with locoregional or oligometastatic lesions. The improve-
ment in PRS could result in prolonged CSS and OS.
Much more recent studies reported that late recurrence 
of gastric cancer occurred beyond 5 and even 10 years after 
curative surgical resection of primary tumor.19– 22 The pres-
ent study also showed that late recurrence occurred in 74 
patients. Among them, 17 (23.0%) patients were diagnosed 
with recurrent gastric cancer after >10 years since curative 
surgical resection (Table  1). Half of these extremely late 
recurrence cases (8/17, 47.1%) were asymptomatic and de-
tected during the follow- up screening. Even though the num-
bers are few (17/305, 5.6%), considering these extremely late 
recurred cases exist, we need to follow- up with long- term 
survivors. In addition, we suggested the relationship between 
the detection of recurrence in the patients without cancer- 
related symptoms and improved survival outcomes of gastric 
cancer patients, even among the long- term survivors. Even 
so, whether an active surveillance program similar to the one 
within 5 years after curative surgical resection is necessary 
for long- term survivors is doubtful because late recurrence is 
still rare compared to early recurrence, and the loci or onset of 
late recurrence is hard to predict. Many researchers suggested 
prognostic factors for late recurrence, including initial stage 
IV,21 inversely lower stage and lesser lymph node invasion 
than early recurrence,22,23 younger age,20,23 and larger tumor 
size.20 In this study, ages at diagnosis of primary gastric carci-
noma were not related to the recurrence- free survival in both 
early- and late- recurrence groups. Late recurrence was more 
frequent in patients with early- stage primary gastric cancer 
and was more likely found as locoregional, lung, or bone 
recurrence (Table 1). Many researchers have suggested that 
cancer dormancy could be a strong candidate for the culprit 
of late recurrence.24 A previous study hypothesized “cancer 
without disease” in an unrecognized patient as local malig-
nant dormancy,25 and the lung, bone marrow, and brain as the 
candidates for the tissue- specific perivascular dormant niche 
of disseminated tumor cells.26 In this respect, site- specific 
late recurrence was possibly related to cancer dormancy and 
its microenvironments. However, at present, the accurate pre-
diction of late recurrence and personalized surveillance are 
still difficult to apply in clinical practice. Further investiga-
tions on more cases of late recurrence are needed.
This study has several limitations. First, we could not as-
sess the quality- adjusted life years. The importance of sur-
vival with a good quality of life becomes more highlighted 
for cancer survivors. If the patients with asymptomatic 
recurrence can live longer than the patients with cancer- 
related symptoms at detection of recurrence, treatment for 
recurrent disease can relieve cancer- related symptoms and 
maintain the patients’ quality of life. Second, a routine sur-
veillance program for long- term survival was not applied. 
Most asymptomatic recurrences were observed by elevated 
tumor markers or incidental findings in the imaging study 
to screen other cancers or diseases. Several symptomatic 
recurrences were observed in the patients who were lost 
to follow- up. Because cancer- related symptom was sub-
jectively felt and expressed by the patients, an objective 
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analysis was difficult. Therefore, an objective risk assess-
ment and long- term surveillance program should be de-
veloped and estimated. Adequate surveillance methods, 
intervals, and risk models in predicting recurrence could 
not yet be established through this study.
Despite these limitations, this study can provide a timely 
reminder regarding the surveillance for recurrence, especially 
in long- term survivors of gastric cancer, in the era of long- 
term survivorship. Based on the OS benefit of asymptomatic 
detection and clinical characteristics of late recurrence, we 
can conceive an active surveillance program beyond 5 years. 
A personalized prediction model for late recurrence, includ-
ing molecular or genetic factors, and cost- effective and sensi-
tive screening methods are needed to be developed in future 
investigations.
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